Search Results - cytomegalovirus

5 Results

Sort By:

Ozonides forms of artemisinins inhibit cytomegalovirus (CMV) replication in vitro and in vivo

INVENTION NOVELTY: This technology involves the use of a derivative of artemisinin as a new therapy for Cytomegalovirus (CMV) infection.VALUE PROPOSITION: CMV infection is recognized as a cause of morbidity and mortality, especially in immunocompromised individuals. CMV is also the most common viral infection in solid organ transplant recipients. Several...

Published: 5/9/2024 | Inventor(s): Ravit Boger, Jonathan Vennerstrom

Keywords(s): Antagonists/Inhibitors, Cytomegalovirus, Disease Indication, Dosed Therapeutic, Infectious Diseases, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Viral Infections

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Infectious Diseases, Clinical and Disease Specializations > Infectious Diseases > Cytomegalovirus, Clinical and Disease Specializations > Infectious Diseases > Viral Infections

Emetine for Inhibition of Human Cytomegalovirus (HCMV)

UNMET NEED: Infection with human cytomegalovirus (HCMV) continues to be a major threat for pregnant women and immunocompromised hosts. Although anti-HCMV therapies are available, development of new agents are desired because of the limited drugs approved for HCMV, the side effects associated with them, and the emergence of resistant viral mutants during...

Published: 5/9/2024 | Inventor(s): Ravit Boger, Marc Ferrer, Juan Marugan, Andres Garcia, Noel Southall, Xin Hu

Keywords(s): Antagonists/Inhibitors, Cytomegalovirus, Disease Indication, Infectious Diseases, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Viral Infections

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases > Cytomegalovirus, Clinical and Disease Specializations > Infectious Diseases > Viral Infections, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities

Artemisinin dimers as potent anti-cytomegalovirus (CMV) agents

UNMET NEED: Infection with cytomegalovirus (CMV) is common in humans and is usually asymptomatic; yet, in immunocompromised hosts, such as transplant recipients and patients with AIDS, CMV infection is associated with significant morbidity and mortality. Cytomegalovirus infection also is the most common congenitally-acquired infection and the leading...

Published: 5/9/2024 | Inventor(s): Gary Posner, Ravit Boger

Keywords(s): Antagonists/Inhibitors, Cytomegalovirus, Disease Indication, Infectious Diseases, Novel, Predicted Novelty, Single, Small Molecules, Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Viral Infections

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases > Cytomegalovirus, Clinical and Disease Specializations > Infectious Diseases > Viral Infections, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities

Novel Cardiac Glycoside Analogs as Anti-Human Cytomegalovirus (HCMV) Agents

Novelty: Novel group of cardiac glycosides shown to have effective anti-HCMV properties for HCMV infection treatment. Value Proposition: HCMV infection is a serious problem in organ transplant patients and congenitally-infected babies. The currently available systemic therapies for HCMV targeting the viral DNA polymerase are associated with significant...

Published: 5/9/2024 | Inventor(s): Ravit Boger

Keywords(s): Antagonists/Inhibitors, Biologics, Carbohydrates, Cytomegalovirus, Disease Indication, Infectious Diseases, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Viral Infections

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases > Cytomegalovirus, Clinical and Disease Specializations > Infectious Diseases > Viral Infections, Technology Classifications > Therapeutic Modalities > Biologics, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Small Molecules

Novel Therapeutic Strategy for Human Cytomegalovirus (HCMV) Infection

Novelty: A novel therapeutic strategy for HCMV infection by modulation of the Wnt signaling pathway. Value Proposition: HMCV infection is a serious threat for pregnant women and the immunocompromised, such as HIV/AIDS patients or solid organ transplant recipients. Currently, the main HCMV treatment is a six-week cycle of intravenous administration of...

Published: 5/9/2024 | Inventor(s): Ravit Boger

Keywords(s): Antagonists/Inhibitors, Biomarker, Clinical Diagnostics, Cytomegalovirus, Disease Indication, In Vitro Diagnostics, Infectious Diseases, Mechanism-of-action Biomarker, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Viral Infections

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases > Cytomegalovirus, Clinical and Disease Specializations > Infectious Diseases > Viral Infections, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities